Celex Oncology Innovations Limited
11085607
Some Concerns
- Current liabilities exceed current assets (-10)
- 1 outstanding charge (-2)
Details
Compliance
Last accounts
31/12/2024
total exemption full
Next accounts due
30/09/2026
Confirmation statement
Last: 05/04/2025
Due 19/04/2026
Industry
Officers
director · Since 28/11/2017
SOLICITOR
BRITISH · ENGLAND · Age 74
Also on 10 other boards
director · Since 21/07/2019
PHARMACEUTICAL CONSULTANT
DANISH · SWITZERLAND · Age 57
director · Since 26/08/2024
RESEARCH AND DEVELOPMENT DIRECTOR
AMERICAN · UNITED STATES · Age 46
Persons with Significant Control
Former PSCs
Mr Laurence John Cohen
Ceased 25/09/2019
Professor Mustafa Bilgin Ali Djamgoz
Ceased 21/11/2024
Dr Vasileios Xeniades
Ceased 08/06/2020
Charges1 outstanding
KRAS PRESERVATION LIMITED (COMPANY NUMBER: 16856121)
CompanyRankvs 97+ SIC 21100 peers69
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Outstanding charges: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/12/2024
Net Worth
£2.3M
Balance sheet strength
Cash
£1.6M
Cash in the bank
Net Current Assets
£1.5M
Working capital
Current Assets
£1.7M
Current Liabilities
£174k
Fixed Assets
£811k
Debtors
£20k
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 9.48 | +£1.5M |
| 2023 | 2.31 | -£43k |
| 2022 | 2.20 | +£800k |
| 2021 | 0.01 | -£8k |
| 2020 | 0.01 | -£6k |
| 2019 | 0.00 | — |
Derived from filed accounts. Not audited figures.